Exelixis (EXEL) announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination ...

A major downgrade, a billion-dollar pipeline gamble, and a patent war--Exelixis investors brace for a wild ride.

Oppenheimer shifts to a neutral stance on Exelixis, questioning differentiation between zanzalintinib and cabozantinib ...

Analyst David Lebowitz from Citi maintained a Buy rating on Exelixis (EXEL – Research Report) and keeping the price target at $38.00.Invest ...

Oppenheimer analysts downgraded Exelixis (NASDAQ:EXEL) stock from Outperform to Perform, adjusting the price target to $33.00 ...

Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product ...

On Friday, Exelixis Inc (EXEL) stock saw a decline, ending the day at $32.38 which represents a decrease of $-1.75 or -5.13% from the prior close of $34.13. The stock opened at $33.49 and touched a ...

Merit Financial Group LLC purchased a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) during the fourth ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $34.13 which represents a slight increase of $1.25 or 3.80% from the prior close of $32.88. The stock opened at $33 and touched a low ...

Exelixis (NASDAQ:EXEL – Get Free Report) had its price target raised by research analysts at Truist Financial from $38.00 to ...

Exelixis, Inc. EXEL announced its preliminary financial results for fiscal 2024 and provided guidance for fiscal 2025. Revenues, on a preliminary basis, for 2024 were approximately $2.165 billion ...

Exelixis said it was notified by the Food and Drug Administration that its treatment for advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic will not be discussed at a meeting.